Amylyx Pharmaceuticals, Inc.
AMLX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,268,395 | $571,378 | $303,367 | $259,283 |
| - Cash | $225,178 | $58,085 | $59,764 | $77,391 |
| + Debt | $5,935 | $5,962 | $1,382 | $1,981 |
| Enterprise Value | $1,049,152 | $519,255 | $244,985 | $183,873 |
| Revenue | $0 | $0 | $0 | -$665 |
| % Growth | – | – | 100% | – |
| Gross Profit | -$19,855 | -$141 | $0 | -$665 |
| % Margin | – | – | – | 100% |
| EBITDA | -$34,266 | -$41,302 | -$37,647 | -$40,494 |
| % Margin | – | – | – | 6,089.3% |
| Net Income | -$34,386 | -$41,443 | -$35,907 | -$37,546 |
| % Margin | – | – | – | 5,646% |
| EPS Diluted | -0.37 | -0.46 | -0.42 | -0.55 |
| % Growth | 19.6% | -9.5% | 23.6% | – |
| Operating Cash Flow | -$30,368 | -$25,248 | -$39,824 | -$59,008 |
| Capital Expenditures | -$24 | -$17 | -$11 | -$20 |
| Free Cash Flow | -$30,392 | -$25,265 | -$39,835 | -$59,028 |